Brief: Third Harmonic Bio Announces Discontinuation Of Phase 1B Study Of Thb001 In Chronic Inducible Urticaria

Third Harmonic Bio

15/12/2022 14:07

Dec 15 (Reuters) - Third Harmonic Bio Inc  THRD.O :
    * THIRD HARMONIC BIO ANNOUNCES DISCONTINUATION OF PHASE 1B
STUDY
OF THB001 IN CHRONIC INDUCIBLE URTICARIA
    * THIRD HARMONIC BIO INC - DECISION FOLLOWS OBSERVATION OF
ASYMPTOMATIC LIVER TRANSAMINITIS IN TWO SUBJECTS ENROLLED IN
FIRST DOSE COHORT OF 200MG BID
    * THIRD HARMONIC BIO INC - EVIDENCE OF CLINICAL ACTIVITY
OBSERVED;
FULL DATA SET TO BE PRESENTED AT UPCOMING SCIENTIFIC CONFERENCE
    * THIRD HARMONIC BIO INC - INITIATING NONCLINICAL STUDIES TO
ELUCIDATE MECHANISM FOR OBSERVED TRANSAMINITIS
    * THIRD HARMONIC BIO INC - CONDUCTED EXTENSIVE MEDICINAL
CHEMISTRY
EFFORT TO IDENTIFY CHEMICALLY DISTINCT NEXT-GENERATION ORAL
WILD-TYPE KIT INHIBITORS

Source text for Eikon:  ID:nGNXc0CXYS 
Further company coverage:  THRD.O 
 ((Reuters.Briefs@thomsonreuters.com;))